Dyadic International, Inc.

Dyadic International, Inc.

DYAI · Nasdaq

Dyadic International, Inc. (DYAI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Dyadic International, Inc. in 2026. The next earnings report is expected on November 11, 2026.

Earnings calendar

Next earnings date

11 Nov 2026

In 82 days

EPS estimate

-0.03

Revenue estimate

1.5M

Past earnings

12 Aug 2026
EPS actual
-0.06 (-71.4%)
estimate -0.04
Revenue actual
961.1K (-6.3%)
estimate 1.0M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
13 May 2026
EPS actual
-0.05 (-25.0%)
estimate -0.04
Revenue actual
1.1M (+22.9%)
estimate 903.8K
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
25 Mar 2026
EPS actual
-0.04 (+11.1%)
estimate -0.05
Revenue actual
564.3K (-58.0%)
estimate 1.3M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Nov 2025
EPS actual
-0.06 (-35.6%)
estimate -0.04
Revenue actual
1.2M (-4.2%)
estimate 1.2M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Dyadic International missed consensus estimates in its latest earnings report, with EPS of -$0.06 missing the -$0.035 estimate and revenue of $961.14 thousand coming in 6.3% below the $1.03 million estimate. In the prior quarter EPS also missed expectations while revenue came in ahead of estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Mark A. Emalfarb
Employees
6
IPO date
16 Jan 2008
ISIN
US26745T1016
Website
dyadic.com

Frequently asked questions

When does Dyadic International, Inc. (DYAI) next report earnings?

Dyadic International, Inc. (DYAI) is scheduled to report earnings on November 11, 2026.

What was Dyadic International, Inc.'s most recent earnings date?

Dyadic International, Inc. (DYAI) last reported earnings on August 12, 2026.

Where is Dyadic International, Inc. stock listed?

Dyadic International, Inc. (DYAI) is listed on Nasdaq.